Milestone Pharmaceuticals' stock fell 50% after the FDA's CRL for CMC issues, but the drug Etripamil has shown efficacy and ...

Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

Milestone Pharmaceuticals (MIST – Research Report) received a Hold rating and price target from TD Cowen analyst Ritu Baral today. The ...

Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did not approve its lead investigational product, Cardamyst. The nasal spray ...

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues. TD Cowen downgraded Milestone Pharmaceuticals ...

Milestone Pharmaceuticals has a 1-year low of $0.75 and a 1-year high of $2.75. The stock’s 50 day moving average is $2.00 and its two-hundred day moving average is $1.83. Large investors have ...

March 28 (Reuters) - Milestone Pharmaceuticals (MIST.O), opens new tab said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of heart condition and had ...

Milestone Pharmaceuticals stock opened at $0.80 on Tuesday. Milestone Pharmaceuticals has a 52 week low of $0.71 and a 52 week high of $2.75. The company’s 50 day moving average price is $1.92 ...

TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone announced the FDA issued a Complete Response Letter regarding its New ...

Milestone Pharmaceuticals shares collapsed on Friday after the U.S. Food and Drug Administration once again turned away the biopharmaceutical company's proposed etripamil nasal spray to treat a ...